Narang Ajit S, Srivastava Anand K
Department of Pharmaceutics, Institute of Technology, Banaras Hindu University, Varanasi 221005, India.
Drug Dev Ind Pharm. 2002 Sep;28(8):1001-13. doi: 10.1081/ddc-120006431.
Clofazimine (CLF) was formulated with polyethylene glycol (PEG) and polyvinyl pyrrolidone (PVP) as a solid solid dispersion (SSD) to increase the aqueous solubility and dissolution rate of the drug. Different molecular weights of PEG (1500, 4000, 6000, and 9000 Da) and PVP (14,000 and 44,000 Da) were used in different drug:carrier weight ratios (1:1, 1:5, and 1:9) and their effect on the dissolution performance of the drug was evaluated in USP Type 2 apparatus using 0.1 N HCl medium. The dissolution rate was compared with corresponding physical mixtures, a currently marketed soft gelatin capsule product, and free CLF. The effect of different methods of preparation (solvent/melt) on the dissolution rate of CLF was evaluated for PEG solid dispersions. Saturation solubility and phase solubility studies were carried out to indicate drug:carrier interactions in liquid state. Infrared (IR) spectroscopy and X-ray diffraction (XRD) were used to indicate drug:carrier interactions in solid state. Improvement in the drug dissolution rate was observed in solid dispersion formulations as compared to the physical mixtures. The dissolution rate improved with the decreasing weight fraction of the drug in the formulation. Polyvinyl pyrrolidone solid dispersion systems gave a better drug release profile as compared to the corresponding PEG solid dispersions. The effect of molecular weight of the PEG polymers did not follow a definite trend, while PVP 14,000 gave a better dissolution profile as compared to PVP 44,000. Improvement in saturation solubility of the drug in the solid dispersion systems was noted in all cases. Further, IR spectroscopy indicated drug:carrier interactions in solid state in one case and XRD indicated reduction in the crystallinity of CLF in another. It was concluded that solid-dispersion formulations of Clofazimine can be used to design a solid dosage form of the drug, which would have significant advantages over the currently marketed soft gelatin capsule dosage form.
氯法齐明(CLF)与聚乙二醇(PEG)和聚乙烯吡咯烷酮(PVP)制成固体分散体(SSD),以提高药物的水溶性和溶出速率。使用不同分子量的PEG(1500、4000、6000和9000 Da)和PVP(14000和44000 Da),并采用不同的药物与载体重量比(1:1、1:5和1:9),在USP 2型装置中使用0.1 N盐酸介质评估它们对药物溶出性能的影响。将溶出速率与相应的物理混合物、市售软胶囊产品以及游离CLF进行比较。针对PEG固体分散体,评估了不同制备方法(溶剂法/熔融法)对CLF溶出速率的影响。进行了饱和溶解度和相溶解度研究,以表明药物与载体在液态下的相互作用。采用红外(IR)光谱和X射线衍射(XRD)来表明药物与载体在固态下的相互作用。与物理混合物相比,固体分散体制剂的药物溶出速率有所提高。溶出速率随制剂中药物重量分数的降低而提高。与相应的PEG固体分散体相比,聚乙烯吡咯烷酮固体分散体系具有更好的药物释放曲线。PEG聚合物分子量的影响没有呈现出明确的趋势,而与PVP 44000相比,PVP 14000具有更好的溶出曲线。在所有情况下,均观察到药物在固体分散体系中的饱和溶解度有所提高。此外,IR光谱在一种情况下表明了药物与载体在固态下的相互作用,XRD在另一种情况下表明了CLF结晶度的降低。得出的结论是,氯法齐明的固体分散体制剂可用于设计该药物的固体剂型,与目前市售的软胶囊剂型相比具有显著优势。